Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Wuhan Huaxin Kangyuan Biomedical is an active Chinese biotech company focused on developing biologic drugs for autoimmune diseases, with its lead candidate UBP-1213 targeting BAFF currently in Phase 1/2 clinical trials for systemic lupus erythematosus. Other companies under the "Kangyuan" name are involved in pharmaceutical manufacturing—especially hormones and herbal extracts—and medical device materials such as blood purification adsorbents and nano-antibodies. The group has R&D collaborations with academic institutions and operates GMP-certified facilities across China.[1][3][4][5][6]
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Kangyuan Biomedical.